Clinical trials: Solid Tumors (Phase 1)
Neoplasms, Solid Tumors
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
This is a Phase 1/1B, non-randomized, open-label, dose-escalation study of robatumumab (SCH 717454, MK-7454) administered in combination with chemotherapy in pediatric participants with solid tumors, to be conducted in…
- Conditions
- Neoplasms, Solid Tumors, Bone Cancer, Kidney Tumor
- Trial name
- NCT00960063
- Testing
- Temozolomide, Vincristine, Ifosfamide
- Volunteers
- 4 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced or Metastatic MTAP-deleted Solid Tumors
An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors
This study is being done to learn more about a new drug called BG-89894 (previously known as SYH2039). Researchers want to see if the drug is safe, how well people can tolerate it, how it moves through the body, and whether it…
- Trial name
- NCT06568614
- Testing
- BG-89894
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 29 people
- Sponsor
- BeOne Medicines
Non-small Cell Lung Cancer, Colorectal Carcinoma
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
- Trial name
- NCT06218914
- Testing
- NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
Lymphoma, Non-Hodgkin, Neoplasms
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
Study CC-90010-ST-001 is an open-label, Phase 1a, dose escalation and expansion, First-in-human (FIH) clinical study of CC-90010 in subjects with advanced or unresectable solid tumors and relapsed and/or refractory advanced…
- Trial name
- NCT03220347
- Testing
- CC-90010
- Where
- 11 sites in France, Italy and 2 more
- Volunteers
- 139 people
- Sponsor
- Celgene
Unspecified Adult Solid Tumor, Protocol Specific
A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors
This is a first in human, open-label, dose escalation and expansion Phase 1 study of SHR-1916 in adult patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT04842630
- Testing
- SHR-1916
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumor
A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors
This study is a single-arm, open, dose-escalation, and dose-expansion phase I clinical trial of QLS12004 in patients with advanced solid tumors, designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary…
- Trial name
- NCT05829616
- Testing
- QLS12004
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Advanced Solid Tumor
Study of LM-102 in Patients With Advance Solid Tumors
This is an open label Phase I/II trial of LM-102 injection, a recombinant humanized monoclonal antibody targeting Claudin 18.2 (CLDN18.2).
- Trial name
- NCT05008445
- Testing
- LM-102 Injection, LM-102 Injection combined with SOC
- Where
- China
- Volunteers
- 11 people
- Sponsor
- LaNova Medicines Development Co., Ltd.
Neoplasms
Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors
Multicenter, open-label, dose-escalation and pharmacokinetic study.
- Trial name
- NCT02688101
- Testing
- DpC
- Where
- 4 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Collaborative Medicinal Development Pty Limited
Solid Tumor
Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)
This is a single sequence 2-period open label study in participants with advanced solid tumors. The purpose of Period 1 of this study is to assess the mass balance to determine drug-related entities present in circulation and…
- Trial name
- NCT06308263
- Testing
- Tuvusertib [14C]Tuvusertib microtracer, Tuvusertib, Tuvusertib + [14C]Tuvusertib microdose bolus injection
- Where
- Hungary
- Volunteers
- 12 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Advanced Solid Tumors, Lymphoma
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
This study is being conducted to evaluate the safety profile and the Maximum Tolerated Dose (MTD) of TAK-901 in adult patients with advanced solid tumors or lymphoma.
- Trial name
- NCT00935844
- Testing
- TAK-901
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Solid Tumors, Cancer
A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors
To evaluate MEDI1191 administered intratumorally in sequential and concurrent combination with intravenous durvalumab in patients with solid tumors.
- Trial name
- NCT03946800
- Testing
- MEDI1191, Durvalumab
- Where
- 11 sites in United States, Spain
- Volunteers
- 61 people
- Sponsor
- MedImmune LLC
Advanced Solid Tumor, Advanced Lymphoma
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 used as a single agent and in combination with systemic therapies in patients with advanced hematological and solid…
- Trial name
- NCT05279300
- Testing
- CS5001, Rituximab, Gemcitabine
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 480 people
- Sponsor
- CStone Pharmaceuticals
Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
The purpose of this study is to estimate the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) regimen and characterize the pharmacokinetics (PK) of brigatinib monotherapy (film-coated tablets and age-appropriate…
- Conditions
- Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, Solid Tumors
- Trial name
- NCT04260009
- Testing
- Brigatinib, Brigatinib AAF
- Sponsor
- Takeda
Neoplasms
Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors
This is a two-part study of a compound called PF-05212384 (also known as PKI-587). The purpose of part 1 is to identify the Maximum Tolerated Dose (MTD) of PF-05212384 using a Continual Reassessment Method (CRM).
- Trial name
- B2151001 (NCT00940498)
- Testing
- PF-05212384 (also known as PKI-587)
- Where
- 9 sites in United States, Spain and 1 more
- Volunteers
- 78 people
- Sponsor
- Pfizer
Tumor, Cancer
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in participants with advanced solid malignancies
- Trial name
- NCT00463814
- Testing
- AZD6244
- Where
- 4 sites in United States, Netherlands and 1 more
- Volunteers
- 58 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic Solid Tumors
PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors
This Phase 1/2a study will explore the safety and efficacy of PTT-936, an Alpha Kinase 1 (ALPK1) activator, used alone or in combination with anti-PD-1/L1 therapy in patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT06244992
- Testing
- PTT-936, Combination of PTT-936 and anti-PD-1/L1 therapy
- Where
- 6 sites in United States, China
- Volunteers
- 68 people
- Sponsor
- Pyrotech Therapeutics, Inc.
Advanced Solid Tumor Malignancies
A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
This is an open-label Phase 1 dose escalation and expansion study of OMP-305B83 in subjects with previously treated solid tumors. Study includes a dose escalation phase and expansion phase.
- Trial name
- NCT02298387
- Testing
- OMP-305B83
- Where
- 4 sites in United States
- Volunteers
- 71 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Advanced Solid Tumor, Metastatic Solid Tumor
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer
- Trial name
- NCT06577987
- Testing
- CID-078 Monotherapy
- Where
- 10 sites in United States
- Volunteers
- 220 people
- Sponsor
- Circle Pharma
Advanced Solid Malignancies
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant…
- Trial name
- NCT03363893
- Testing
- CT7001, Fulvestrant
- Where
- 23 sites in United States, United Kingdom
- Volunteers
- 124 people
- Sponsor
- Carrick Therapeutics Limited
Advanced Solid Tumors
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult…
- Trial name
- ARTEMIDE-subQ (NCT07161414)
- Testing
- IV Rilvegostomig, Recombinant Human Hyaluronidase (rHu), SC Rilvegostomig
- Where
- 11 sites in United States, South Korea and 2 more
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.